METTL3 and neoplasm: Overall, in the clinical treatment of BCa, targeting METTL3 could present novel therapeutic strategies to overcome chemotherapy and immunotherapy resistance driven by tumor angiogenesis, thereby improving the clinical outcomes of patients.